UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
____________
FORM 10-Q/A
(Amendment No. 1)
x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended March 31, 2010
OR
o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from to
Commission File Number 001-31668
INTEGRATED BIOPHARMA, INC.
(Exact name of registrant, as specified in its charter)
Delaware | 22-2407475 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
225 Long Ave., Hillside, New Jersey | 07205 |
(Address of principal executive offices) | (Zip Code) |
(888) 319-6962
(Registrant's telephone number, including Area Code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer | Accelerated filer | Non-accelerated filer | Smaller reporting company x |
Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No x
Applicable only to Corporate Issuers:
The number of shares outstanding of each of the issuer’s class of common stock, as of the latest practicable date:
Class | Outstanding at May 19, 2010 |
Common Stock, $0.002 par value | 20,519,342 Shares |
Explanatory Statement
This Amendment No. 1 amends Integrated BioPharma, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 which was filed with the Securites and Exchange Commission on May 19, 2010. The Company is filing this Amendment No. 1 to correct a typographical error found in the Signature page to the original filing. Accordingly, the Signature page has been amended to reflect a correction of the typographical error.
This Amendment No. 1 does not include the entire Form 10-Q except as described in this explanatory note. This Amendment No. 1 does not amend any other information set forth in the original filing.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INTEGRATED BIOPHARMA, INC.
Date: May 19, 2010 | By: | /s/ E Gerald Kay | |
E. Gerald Kay, | |||
President and Chief Executive Officer |
Date: May 19, 2010 | By: | /s/ Dina L. Masi | |
Dina L. Masi, | |||
Chief Financial Officer & Senior Vice President |
34